TD Private Client Wealth’s Medifast MED Stock Holding History

TD Private Client Wealth’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-66	Closed	-$902	–	1689
2025 Q3	$902	Buy	+66	New	+$922	﹤0.01%	1348

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

TD Private Client Wealth's MED Position: Q4 2025 in Review

TD Private Client Wealth sold out of Medifast (MED) in Q4 2025, closing a stake of 66 shares — an estimated $902 sold.

TD Private Client Wealth first reported a position in MED in Q3 2025 and held it in 1 quarter. The position peaked at $902 in Q3 2025. 109 funds tracked by Wall St. Rank hold MED as of Q4 2025.

TD Private Client Wealth reported no remaining Medifast position as of Q4 2025 after selling out during the quarter.
TD Private Client Wealth sold 66 Medifast shares in Q4 2025, an estimated $902.
TD Private Client Wealth first reported a position in Medifast in Q3 2025 and held it in 1 quarter.
TD Private Client Wealth's Medifast position peaked at $902 in Q3 2025.
109 funds tracked by Wall St. Rank held Medifast as of Q4 2025.

Based on TD Private Client Wealth's 13F filing for Q4 2025, filed 5 Feb 2026.